PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage
Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.
This corporate disclosure from was processed by Pulse News Wire on January 13, 2026. It represents a primary source document for Japanese Compensation sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.
Source disclosure: January 13, 2026 Kringle Pharma,Inc. [4884.T] TOKYO, Jan 13 (Pulse News Wire) – Kringle Pharma,inc. (4884.T) completed the issuance of restricted shares as part of executive compensation. The issuance was approved during the board meeting held on December 22, 2025. A total of 50,000 ordinary shares were allocated to five executives, excluding external directors, at a par value of ¥381 per share based on the closing price on December 22, 2025. Details of the share